SNOA — Sonoma Pharmaceuticals, Inc.

—
Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1367083 ·
Last close
$0.83
Market Cap
$4.22M
52W High
$3.95
52W Low
$0.80
ADV30
71,901
Next earnings
—
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 7,174,000 2,807,000 290,000 -66,000 17,103,000 4,609,000 10,489,000
Jun 2026 6,406,000 2,577,000 -40,000 -330,000 18,107,000 5,338,000 11,513,000
Mar 2026 5,561,000 2,181,000 -351,000 -581,000 13,960,000 2,399,000 10,865,000
Dec 2025 4,349,000 1,650,000 -678,000 -819,000 13,623,000 2,561,000 10,191,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-2,567,000
Investing CF
$-88,000
Financing CF
$3,989,000
CapEx
$-88,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-1.65
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-201,311,000
Inventory
$3,786,000
Receivables
$3,182,000
ST Investments
—
EBIT TTM
$-1,406,000
Pretax Income TTM
$-2,507,000
Interest Exp TTM
—
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$23,490,000
EBITDA
$-650,000
Free Cash Flow
$-1,473,875
Enterprise Value
$1,510,136
Total Cash
$4,609,000
Total Debt
$602,000
Shares Out
5,061,593
Trailing EPS
$-1.22
Book Value
$1.31
ROE
-34.5%
ROA
-3.1%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Mar 2026 19,529,000 -2,461,000 -3,175,000 13,960,000 10,865,000 3,095,000 -3,933,000
Mar 2025 14,288,000 -3,710,000 -3,457,000 13,693,000 9,282,000 4,411,000 -88,000
Mar 2024 12,735,000 -4,701,000 -4,835,000 14,740,000 8,603,000 6,137,000 -2,398,000
Mar 2023 13,272,000 -4,570,000 -5,151,000 16,231,000 8,254,000 7,977,000 -6,152,000

TTM Snapshot

Revenues TTM
$21,920,000
NetIncome TTM
$-2,264,000
OpCashFlow TTM
—
Assets (Latest)
$18,107,000
Forward EPS
$-0.56

Peers — same industry

TickerNameMarket CapLastDaily %
ICU SeaStar Medical Holding Corp $4.15M $0.78 —
TUTH Standard Dental Labs Inc. $4.10M $0.13 —
NVNO enVVeno Medical Corp $4.01M $5.77 —
MHUAF Meihua International Medical Technologies Co., Ltd. $4.71M $5.50 —
OSRH OSR Health, Inc. $3.51M $0.10 —

News headlines (Yahoo Finance, 1h cache)

Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2027 Financial Results, Delivering First-ever Net Income Before Income Tax
2026-11-10 21:10 · Yahoo
Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA
2026-08-06 13:00 · Yahoo
Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution
2026-06-30 13:00 · Yahoo
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results
2026-06-16 20:15 · Yahoo
Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering
2026-04-24 13:21 · Yahoo
Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart
2026-03-24 12:30 · Yahoo
Sonoma Pharmaceuticals Announces Launch of New Dermatology Product Line under Person & Covey's Aquanil Brand for Sensitive Skin
2026-03-18 12:30 · Yahoo
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results
2026-02-10 21:10 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.